REGENXBIO (NASDAQ:RGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS

REGENXBIO (NASDAQ:RGNX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26, Zacks reports. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.

REGENXBIO Stock Performance

RGNX opened at $6.72 on Friday. The company has a market cap of $332.94 million, a PE ratio of -1.34 and a beta of 1.35. The stock has a 50-day moving average of $7.34 and a 200-day moving average of $9.08. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $23.14.

Wall Street Analysts Forecast Growth

RGNX has been the subject of a number of research analyst reports. Morgan Stanley increased their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of REGENXBIO in a research note on Wednesday, January 15th. Raymond James began coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. Finally, The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and lowered their target price for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.13.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.